Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7678905 | 0.76 | CTSK (0.37) | TDP1 | |
| SCHEMBL19008276 | 0.74 | KISS1R (0.34) | — | |
| SCHEMBL18643032 | 0.73 | — | — | |
| SCHEMBL25157049 | 0.70 | TDP1 (0.30) | TDP1 | |
| SCHEMBL15375249 | 0.70 | TSHR (0.41) | — | |
| SCHEMBL9418800 | 0.70 | — | — | |
| SCHEMBL27855255 | 0.68 | TSHR (0.33) | — | |
| SCHEMBL18570868 | 0.67 | ADH1B (0.43) | — | |
| SCHEMBL11523628 | 0.67 | PLA2G2C (0.39) | TDP1 | |
| SCHEMBL21477642 | 0.67 | TSHR (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044095-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | Ketogen, Inc. (CA) | 2017-02-16 | — | — | US | disclosed |
| US-9481637-B2 | Compounds for the treatment of seizures and other central nervous systems disorders and conditions | Ketogen Inc. (CA) | 2016-11-01 | — | — | US | disclosed |
| US-20150344413-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | Ketogen Inc. (CA) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044095-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | PC, PYGB, GLS2 | TDP1 2922/4885MMP9 4226/4885 |
| US-20150344413-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | PC, PYGB, GLS2 | TDP1 2922/4885MMP9 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.